N-乙基-N-[4-[[4-[乙基[(3-磺基苯基)甲基]氨基]苯基](2-磺基苯基)亚甲基]-2,5-环己二烯-1-亚基]-3-磺基-苯甲铵内盐钾钠盐 | 68921-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-N-[4-[[4-[乙基[(3-磺基苯基)甲基]氨基]苯基](2-磺基苯基)亚甲基]-2,5-环己二烯-1-亚基]-3-磺基-苯甲铵内盐钾钠盐
• 英文名称: Erioglaucin-A
• 英文别名: 4',4''-bis-[ethyl-(3-sulfo-benzyl)-amino]-2-sulfo-tritylium betaine；4',4''-Bis-[aethyl-(3-sulfo-benzyl)-amino]-2-sulfo-tritylium-betain；2-[[4-[ethyl-[(3-sulfophenyl)methyl]amino]phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]benzenesulfonate
• CAS: 68921-42-6；25305-78-6
• 化学式: C₃₇H₃₆N₂O₉S₃
• 分子量: 748.899
• InChiKey: CTRXDTYTAAKVSM-UHFFFAOYSA-N

物化性质

• 颜色/状态：
  Reddish-violet powder or granules with a metallic luster
• 熔点：
  283 °C (decomposes)
• 溶解度：
  In water, 30 mg/mL (3.0X10+4 mg/L)
• 分解：
  When heated to decomposition it emits very toxic fumes of /nitrogen sodium, and sulfur oxides/.

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  51
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  197
• 氢给体数：
  2
• 氢受体数：
  10

ADMET

毒理性

• 相互作用

尽管单个焦油食品色素根据可接受日摄入量（ADI）进行控制，但目前尚无明确信息说明这些添加剂组合如何影响食品安全。在当前研究中，对单一使用和组合使用色素对神经祖细胞（NPC）毒性的效力进行了检测，NPC是发育阶段的生物标志物，以及对神经发生的影响，这反映了成年中枢神经系统（CNS）的功能。/亮红AC/和/苋菜红/在小鼠多能NPC中减少了NPC的增殖和存活率，在发育中的CNS模型中。在测试的几种组合中，/柠檬黄/和/亮蓝FCF/的组合在韩国平均日摄入量的1000倍以上时，显著减少了成年小鼠海马区新生成细胞数量，表明对海马神经发生有强烈的负面影响。然而，包括/亮红AC/和/苋菜红/在内的其他组合并未影响齿状回的成年海马神经发生。证据表明，大多数焦油食品色素的单一使用和组合使用在发育NPC和成年海马神经发生方面可能是安全的。然而，对/柠檬黄/和/亮蓝FCF/过高剂量组合的反应表明可能有协同效应，以抑制成年海马区NPC的增殖。数据表明，焦油色素的组合可能对发育中和成年海马神经发生产生不利影响...

Although individual tar food colors are controlled based on acceptable daily intake (ADI), there is no apparent information available for how combinations of these additives affect food safety. In the current study, the potencies of single and combination use of /dyes/ were examined on neural progenitor cell (NPC) toxicity, a biomarker for developmental stage, and neurogenesis, indicative of adult central nervous system (CNS) functions. /Allura red AC/ and /amaranth/ reduced NPC proliferation and viability in mouse multipotent NPC, in the developing CNS model. Among several combinations tested in mouse model, combination of /tartrazine /and /brilliant blue FCF / at 1000-fold higher than average daily intake in Korea significantly decreased numbers of newly generated cells in adult mouse hippocampus, indicating potent adverse actions on hippocampal neurogenesis. However, other combinations including /allura red AC/ and /amaranth/ did not affect adult hippocampal neurogenesis in the dentate gyrus. Evidence indicates that single and combination use of most tar food colors may be safe with respect to risk using developmental NPC and adult hippocampal neurogenesis. However, the response to excessively high dose combination of /tartrazine/ and /brilliant blue FCF/ suggestive of synergistic effects to suppress proliferation of NPC in adult hippocampus. Data indicated that combinations of tar colors may adversely affect both developmental and adult hippocampal neurogenesis...

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下），以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗帮助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

/CASE REPORTS/ ... 报告了两例危重病人出现难治性休克和代谢性酸中毒的病例。这些病人接受了添加了亮蓝FCF的肠内营养配方，以便于检测误吸。... 第一个病人的剂量没有超过0.7毫克/千克体重/天，第二个病人的剂量没有超过2毫克/千克体重/天。... 尽管在健康受试者中，亮蓝FCF的吸收似乎有限，但危重病人的胃肠道对亮蓝FCF的渗透性增加，这是由于肠上皮细胞死亡和肠上皮细胞中应激诱导的神经内分泌因子的释放所致。

/CASE REPORTS/ ... Two cases of refractory shock and metabolic acidosis in critically ill patients are reported. The patients received Brilliant Blue FCF added to enteral nutrition formulations in order to facilitate the detection of aspiration. ... The dose did not exceed 0.7 mg/kg bw/day for the first patient and 2 mg/kg bw/day for the second one. ... Although in healthy subjects absorption of Brilliant Blue FCF appears to be limited, critically ill patients have increased gastrointestinal permeability to Brilliant Blue FCF secondary to enterocyte death and stress induced release of neuro-endocrine factors in the intestinal epithelium.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

（14）C标记的绿色S和亮蓝色FCF在大鼠、小鼠和豚鼠中的吸收、代谢和排泄情况已被研究。在给雄性或雌性大鼠单次口服绿色S 100微克/千克或亮蓝色FCF 10毫克/千克，以及绿色S 30微克/千克或亮蓝色FCF 3毫克/千克后，大部分剂量在72小时内以未改变的形式随粪便排出。在给（14）C标记的色素之前，通过饲料预先给雄性大鼠未标记的绿色S或亮蓝色FCF（分别为100毫克/千克/天或30毫克/千克/天）处理21天，对此途径的排泄或消除所有标记物所需的时间没有影响。同样，雄性小鼠和豚鼠也随粪便排出了单次口服的绿色S或亮蓝色FCF的全部剂量。通过对孤立的小肠环的研究，确认了所有三种研究物种的胃肠道对标记染料的吸收和代谢不足。研究显示，给怀孕大鼠（14）C标记的绿色S或亮蓝色FCF后，胎儿没有摄取到放射性。

The absorption, metabolism and excretion of (14)C-labelled Green S and Brilliant Blue FCF have been studied in the rat, mouse and guinea-pig. Following administration of a single oral dose of Green S at either 100 ug/kg or 10 mg/kg of Brilliant Blue FCF at either 30 ug/kg or 3 mg/kg to male or female rats, substantially all of the dose was excreted unchanged in the feces within 72 hr. Pretreating male rats with unlabelled Green S or Brilliant Blue FCF in the diet (100 or 30 mg/kg day, respectively) for 21 days prior to dosing with (14)C-labelled coloring had no effect on the route of excretion or the time taken to eliminate all of the label. Similarly male mice and guinea-pigs excreted in the feces all of a single oral dose of Green S or Brilliant Blue FCF. The lack of absorption and metabolism of the labelled dye in the gastro-intestinal tract of all three species investigated was confirmed by studies using isolated loops of small intestine. It was shown that no radioactivity was taken up by the fetuses of pregnant rats given (14)C-labelled Green S or Brilliant Blue FCF.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

Sprague-Dawley雌性大鼠通过灌胃给予单次剂量的(14)C标记色素（0.27毫克；1.74微居里）。在胆管结扎的大鼠中，FD & C蓝NO.1的肠吸收量（从口服给药后96小时内的尿液(14)C排泄、呼出的(14)CO2以及内脏和组织的残留放射性估计）平均为剂量的2.05%。平均粪便排泄量为97.28%，施用放射性的总回收率为99.38%。完整大鼠对(14)C-FD & C蓝NO.1的肠吸收平均仅为0.27%（91%回收率），而在胆管插管动物中的胆汁排泄量平均为剂量的1.32%。尿液和胆汁样本的薄层色谱分析显示，约95%的排泄放射性是未改变的FD & C蓝NO.1，约5%是FD & C蓝NO.1的一种未识别的代谢物或降解产物。结果表明，FD & C蓝NO.1从胃肠道的吸收很差，并且吸收的化合物随后会经历快速而完全的胆汁排泄。

Female Sprague-Dawley rats were given a single dose (0.27 mg; 1.74 uCi) of the (14)C-labelled coloring by gavage. In bile-duct ligated rats, intestinal absorption of FD & C Blue No.1 (estimated from urinary (14)C excretion, expired (14)CO2 and residual radioactivity in internal organs and tissues 96 hr after oral administration) averaged 2.05% of the dose. Mean fecal excretion was 97.28% and the total recovery of administered radioactivity was 99.38%. Intestinal absorption (14)C-FD & C Blue No. 1 in intact rats averaged only 0.27% (91% recovery), while biliary excretion in bile-duct cannulated animals averaged 1.32% of the dose. Thin-layer chromatography of urine and bile samples revealed that about 95% of excreted radioactivity was unaltered FD & C Blue No. 1 and that about 5% was an unidentified metabolite or degradation product of FD & C Blue No. 1. The results show that FD & C Blue No.1 is poorly absorbed from the gastro-intestinal tract, and undergoes subsequent rapid and complete biliary excretion /of the absorbed compound/.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在5小时内，大鼠胆汁中排出的标记剂量（3毫克/千克体重）小于0.05%。在妊娠第8天口服给予（14）C标记的亮蓝FCF的怀孕大鼠中，第11天在胎儿中检测到的放射性非常低（剂量的0.004 - 0.006%）。亮蓝FCF在中心甲烷环上用（14）C标记，其放射性纯度超过95%。

... Less than 0.05% of a labeled dose of 3 mg/kg bw was excreted in the bile of rats over a 5-hour period. Very little radioactivity (0.004 - 0.006% of dose) was detected on day 11 in the fetuses of pregnant rats given (14)C-labelled Brilliant Blue FCF orally on day 8 of gestation. ... Brilliant Blue FCF was labeled with (14)C in the central methane ring and had a radioactive purity of greater than 95%. ...

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在给雄性或雌性大鼠通过灌胃给予30微克/千克体重或3毫克/千克体重的(14)C-亮蓝色FCF后，几乎所有剂量的药物在72小时内未发生变化地通过粪便排出（低剂量时为99.9%，高剂量时为95.4%）。在呼出的空气中没有检测到放射性，尿液中检测到的量少于0.5%。...

Following administration of either 30 ug/kg bw or 3 mg/kg bw of (14)C-Brilliant Blue FCF by gavage to male or female rats, substantially all of the dose was excreted unchanged in the feces within 72 hours (99.9% at low dose, 95.4% at high dose). No radioactivity was detected in the expired air and less than 0.5% was detected in the urine. ...

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  4-氟-3-硝基苯甲酸 、 N-乙基-N-[4-[[4-[乙基[(3-磺基苯基)甲基]氨基]苯基](2-磺基苯基)亚甲基]-2,5-环己二烯-1-亚基]-3-磺基-苯甲铵内盐钾钠盐 在 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 二氯甲烷 为溶剂， 反应 16.5h， 生成 3,3-dimethyl-N-(6-nitro-2,3-dihydro-1H-indol-5-yl)butanamide
  参考文献：
  名称：

  [EN] PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS
  [FR] INHIBITEURS DE PHOSPHLOLIPASE C DESTINES A ETRE UTILISE DANS LE TRAITEMENT DE TROUBLES INFLAMMATOIRES

  摘要：

  公开号：

  WO2004087685A3
• 作为产物：
  描述：

  在 哌啶 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.5h， 生成 N-乙基-N-[4-[[4-[乙基[(3-磺基苯基)甲基]氨基]苯基](2-磺基苯基)亚甲基]-2,5-环己二烯-1-亚基]-3-磺基-苯甲铵内盐钾钠盐
  参考文献：
  名称：

  [EN] PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS
  [FR] INHIBITEURS DE PHOSPHLOLIPASE C DESTINES A ETRE UTILISE DANS LE TRAITEMENT DE TROUBLES INFLAMMATOIRES

  摘要：

  公开号：

  WO2004087685A3

文献信息

• Apparatuses and methods for generating a high-concentration protein product from a blanched biomass
  申请人：PARABEL LTD.

  公开号：US10194684B2

  公开（公告）日：2019-02-05

  The present disclosure relates, according to some embodiments, to apparatuses and methods for blanching (e.g., continuously) a microcrop (e.g., aquatic species, Lemna) and a high-concentration protein product derived therefrom. The present disclosure relates, according to some embodiments, to an apparatus for blanching a microcrop (e.g., Lemna, Wolffia) where the apparatus may include: a conveyance mechanism operable to transport a biomass to a blanching tray; an applicator operable to dispense a blanching solution onto at least one surface of the biomass within the blanching tray; the blanching tray oriented to receive a volume of the blanching solution from the applicator; and a vibratory mechanism capable of vibrating the blanching tray to generate a net motion of the received volume of the blanching solution within blanching tray such that a wave of blanching solution is formed. In some embodiments, a vibratory mechanism may be operable to generate a motive force capable of directing a biomass from a first side of a blanching tray to a second side of the blanching tray. In some embodiments, an apparatus may be capable of processing a biomass at a product flow rate ratio of about 7:1.

  根据一些实施例，本公开涉及用于焯水（例如连续焯水）微型作物（例如水生物种Lemna）和由此衍生的高浓度蛋白质产品的装置和方法。根据某些实施例，本公开涉及一种用于焯烫微型作物（例如、Lemna, Wolffia），该装置可包括：输送机构，可将生物质输送到焯水盘中；涂抹器，可将焯水溶液涂抹到焯水盘中生物质的至少一个表面上；焯水盘，可从涂抹器接收一定量的焯水溶液；以及振动机构，可振动焯水盘，使焯水盘中接收的焯水溶液产生净运动，从而形成焯水溶液波。在一些实施例中，振动机构可产生动力，将生物质从焯烫盘的第一侧导向焯烫盘的第二侧。在某些实施例中，设备可按约 7:1 的产品流速比处理生物质。
• Oral soluble film containing sildenafil citrate
  申请人：CURE Pharmaceutical Holding Corp.

  公开号：US11179331B1

  公开（公告）日：2021-11-23

  The present invention relates to an oral soluble film (OSF), methods of orally administering the same, and methods of manufacturing the same. The oral soluble film includes sildenafil citrate, and can further include a binder, filler, flavoring agent, plasticizer, sweetening agent, preservative, solvent, and optionally coloring agent. The active ingredient and excipients can be provided and present in an amount effective to achieve desired physical and performance characteristics of the OSF.

  本发明涉及一种口服可溶性薄膜（OSF）、口服该薄膜的方法以及制造该薄膜的方法。口服可溶膜包括枸橼酸西地那非，还可进一步包括粘合剂、填料、调味剂、增塑剂、甜味剂、防腐剂、溶剂和可选着色剂。活性成分和辅料的用量可以达到口服溶液膜所需的物理和性能特征。
• Bicomponent composition
  申请人：HFC Prestige International Holding Switzerland S.a.r.l

  公开号：US11324688B2

  公开（公告）日：2022-05-10

  The instant disclosure generally relates to a bicomponent composition for coloring mammalian or synthetic keratin fibers, the bicomponent composition comprising first, second, components. The first component includes an organic polymer, the second component includes a pretreatment base compound. One or more of the components includes pigment microparticles. The bicomponent composition combines upon application to treated material such as hair, forms a solid coating thereon and has a substantially long color fastness following development (setting). Methods of using such compositions are also described herein.

  本公开一般涉及一种用于给哺乳动物或合成角蛋白纤维着色的双组分组合物，该双组分组合物包括第一和第二组分。第一组分包括有机聚合物，第二组分包括预处理基础化合物。其中一种或多种成分包括颜料微粒。双组分组合物在涂抹到经过处理的材料（如头发）上时，会在其上形成一层固体涂层，并在显色（固色）后具有相当长的色牢度。本文还介绍了使用这种组合物的方法。
• Methods and systems for extracting reduced oxalic acid protein from aquatic species and compositions thereof
  申请人：Parabel Nutrition, Inc.

  公开号：US11325941B2

  公开（公告）日：2022-05-10

  The present disclosure relates, according to some embodiments, to methods and systems for purifying proteins having a reduced oxalic acid content from aquatic species and compositions thereof.

  根据一些实施例，本公开涉及从水生物种中纯化草酸含量降低的蛋白质及其组合物的方法和系统。
• COSMETIC COMPOSITION
  申请人：Intercos S.p.A.

  公开号：EP3166576B1

  公开（公告）日：2019-02-20